Regeneron Pharmaceuticals Inc. has announced interim results from the ongoing Phase 2 COURAGE trial, which is investigating new combinations of the GLP-1 receptor agonist semaglutide with trevogrumab and, potentially, garetosmab for treating obesity. The trial indicates that approximately 35% of weight loss induced by semaglutide is attributed to lean mass loss. The study found that combining semaglutide with muscle-preserving antibodies such as trevogrumab, with or without garetosmab, can protect lean mass, preserving about 50%-80% of the lean mass lost when using semaglutide alone, while also increasing fat mass loss. This suggests a potential improvement in the quality of weight loss for patients undergoing GLP-1 therapy. The trial consists of two 26-week phases, with the current data available only from the weight-loss phase. Further data from the weight-maintenance phase is expected later this year. Safety data showed varying levels of treatment emergent adverse events across different treatment groups, with the highest in the triplet group. Two deaths were reported in the triplet group, though no causal association with the treatment has been identified. The full data set will provide further insights to optimize future dosing regimens.